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Interferon (IFN) induces an antiviral state in cells that results in alterations of the patterns and
levels of parainfluenza virus type 5 (PIV5) transcripts and proteins. This study reports that IFN-
stimulated gene 56/IFN-induced protein with tetratricopeptide repeats 1 (ISG56/IFIT1) is
primarily responsible for these effects of IFN. It was shown that treating cells with IFN after
infection resulted in an increase in virus transcription but an overall decrease in virus protein
synthesis. As there was no obvious decrease in the overall levels of cellular protein synthesis in
infected cells treated with IFN, these results suggested that ISG56/IFIT1 selectively inhibits the
translation of viral mRNAs. This conclusion was supported by in vitro translation studies. Previous
work has shown that ISG56/IFIT1 can restrict the replication of viruses lacking a 29-O-
methyltransferase activity, an enzyme that methylates the 29-hydroxyl group of ribose sugars in the
59-cap structures of mRNA. However, the data in the current study strongly suggested that PIV5
mRNAs are methylated at the 29-hydroxyl group and thus that ISG56/IFIT1 selectively inhibits the
translation of PIV5 mRNA by some as yet unrecognized mechanism. It was also shown that
ISG56/IFIT1 is primarily responsible for the IFN-induced inhibition of PIV5.
INTRODUCTION
Parainfluenza virus type 5 [PIV5; previously known as
simian virus 5 (SV5)] is a member of the genus Rubula-
virus in the subfamily Paramyxovirinae of the family
Paramyxoviridae (Lamb & Parks, 2006). Like other
paramyxoviruses, PIV5 is an enveloped virus with a non-
segmented negative-sense RNA genome of 15 246 bases
with seven tandemly linked genes that encode eight
proteins. The RNA genome encodes, from the 39 end, the
nucleo- (NP), phospho- (P), V, matrix (M), fusion (F),
small hydrophobic (SH), haemagglutinin–neuraminidase
(HN) and large (L) proteins. All viral RNA synthesis is
initiated at or close to the 39 end of the genomic or
antigenomic RNA. During transcription, the viral poly-
merase recognizes gene-start and gene-stop sequences in
the genomic RNA, resulting in the generation of individual
mRNAs that are also capped and polyadenylated by the
viral polymerase. Failure of the polymerase to reinitiate at
downstream gene-start sites, or disengagement of the
polymerase from the genome, results in a transcriptional
gradient, with the NP gene being transcribed the most
frequently and the L gene the least. The second gene, the V/
P gene, encodes both the P and the V proteins using an
RNA editing mechanism. During replication, the poly-
merase must ignore the gene-start and gene-stop signals to
make full-length copies of either the genomic or anti-
genomic template. As with other negative-strand RNA
viruses, the polymerase does not replicate or transcribe
naked RNA but rather uses the ribonucleoprotein complex
as its template (for a general review of the molecular biology
of paramyxovirsues, see Lamb & Parks, 2006, and for an
extensive recent review on PIV5, see Parks et al., 2011).
Like other viruses, to survive in nature, PIV5 has to
circumvent, at least partially, the interferon (IFN) response
(Randall & Goodbourn, 2008). The IFN response is
triggered when virus infection results in the generation of
molecules, such as dsRNA, that display molecular signa-
tures, termed pathogen-associated molecular patterns
(PAMPs), that are not found in uninfected cells and that
are recognized by cellular receptors, termed pattern
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recognition receptors (PRRs) (Kumar et al., 2011). The two
most important cytoplasmic PRRs for detecting PAMPs
produced by RNA viruses are retinoic acid-inducible gene I
(RIG-I) and melanoma differentiation-associated gene 5
(MDA-5). RIG-I preferentially recognizes uncapped 59-
triphosphate RNA molecules that have a short stretch
of dsRNA, whilst MDA-5 recognizes longer molecules
of dsRNA that do not need to be 59 triphosphorylated
(Schmidt et al., 2011). Upon binding their appropriate
ligands, both RIG-I and MDA-5 initiate a signalling
cascade that results in the secretion of IFN-b from the
infected cells. The secreted IFN then acts in an autocrine
and paracrine manner to upregulate the expression of
hundreds of cellular genes, many of which have direct or
indirect antiviral activity (Randall & Goodbourn, 2008).
PIV5 has a number of strategies to minimize the
effectiveness of the IFN response. It encodes an IFN
antagonist, the V protein, which limits the production of
IFN and blocks IFN signalling (reviewed by Goodbourn &
Randall, 2009; Ramachandran & Horvath, 2009). The V
protein limits IFN induction by interacting directly with
MDA-5, preventing it from binding dsRNA and thus
preventing activation of the IFN induction cascade
(Andrejeva et al., 2004; Childs et al., 2009). Furthermore,
whilst the V protein does not bind directly to RIG-I, it
indirectly inhibits RIG-I by binding to Laboratory of
Genetics and Physiology 2 protein (LGP2, a helicase related
to RIG-I and MDA-5), stabilizing the interaction of LGP2
with RIG-I, thereby inhibiting RIG-I (Childs et al., 2012).
In addition, it can act as a competitive inhibitor of TANK-
binding kinase 1 (TBK1), reducing its ability to phosphor-
ylate IFN regulatory factor 3 (IRF-3) (Lu et al., 2008). The
V protein also blocks IFN signalling by targeting signal
transducer and activator of transcription 1 (STAT1) for
proteasome-mediated degradation (Didcock et al., 1999)
by a mechanism that requires it to act as a bridge between a
cellular E3 ubiquitin ligase and STAT1/STAT2 hetero-
dimers (Parisien et al., 2002; Precious et al., 2005). In
addition, to these mechanisms, PIV5 tightly controls the
transcription and replication of its genome, thereby limit-
ing the production of PAMPs that may activate the IFN
induction cascade (Goodbourn & Randall, 2009; Parks
et al., 2011). Indeed, recent evidence suggests that PIV5
does this so successfully that PAMPs that activate the IFN
induction cascade are not produced during normal virus
replication (Killip et al., 2011, 2012). Instead, PAMPs that
activate the IFN response are produced primarily by defective
interfering particles that are generated during aberrant virus
replication (Chen et al., 2010; Killip et al., 2011).
Despite these IFN-evasive mechanisms and strategies, the
ability of PIV5 to circumvent the IFN response is not
absolute, as witnessed by the observation that plaques of
PIV5 are significantly larger on cells that cannot produce
and/or respond to IFN compared with IFN-competent cells
(Carlos et al., 2009; Young et al., 2003). During plaque
development, a few, rather than all, infected cells produce
the IFN that induces an antiviral state in the surrounding
uninfected cells (Chen et al., 2010). Whilst the replication
of PIV5 is severely restricted in cells in an IFN-induced
antiviral state (Carlos et al., 2005), nevertheless the
virus manages to target STAT1 for proteasome-mediated
degradation (Didcock et al., 1999; Precious et al., 2007). As
a consequence, in the absence of continuous stimulation by
IFN, the cell cannot maintain its antiviral state indef-
initely, and within 24–48 h, the virus manages to establish
a normal pattern of virus replication (Carlos et al., 2009).
To study the effects of IFN on the replication of PIV5, we
have developed systems in which cells that cannot produce
IFN but can respond to IFN are infected with an isolate of
PIV5, termed CPI2, that does not block IFN signalling
because it fails to target STAT1 for proteasome-mediated
degradation (Chatziandreou et al., 2002a). It is thus
possible to infect such ‘IFN-compromised’ cells with
CPI2 to allow the virus to establish a normal replication
pattern and then at various time post-infection (p.i.) to
add IFN to the culture medium and monitor the effects of
IFN on virus replication and protein synthesis (Carlos et al.,
2005). Using this system, we have shown previously that
the addition of IFN to cells actively synthesizing CPI2
proteins alters the pattern of virus mRNA transcription
and induces a marked reduction in virus protein synthesis,
particularly of the M and HN proteins (Carlos et al., 2005).
Using this system, we showed that myxovirus A (MxA),
protein kinase R (PKR) and oligoadenylate synthetase
(OAS)/RNase L are not responsible for the alteration in
virus protein synthesis observed following IFN treatment
(Carlos et al., 2007). Here, we present evidence that IFN-
stimulated gene 56/IFN-induced protein with tetratrico-
peptide repeats 1 (ISG56/IFIT1) is primarily responsible for
the observed effects of IFN on PIV5 transcription and
protein synthesis.
RESULTS
ISG56/IFIT1 is primarily responsible for the
IFN-induced alterations to the pattern of PIV5
protein synthesis
We have shown previously that PKR, OAS and Mx are not
the major IFN-inducible activities that limit PIV5 replica-
tion (Carlos et al., 2007). To attempt to identify the
IFN-stimulated gene (ISG) primarily responsible for the
IFN-induced inhibition of PIV5, cells were transiently
transfected with plasmids permitting the constitutive
expression of IFIT3, IFN-induced protein 35 (IFI35),
ISG15, ISG20, viperin or ISG56/IFIT1, and the cells were
subsequently infected with a variant of PIV5, CPI2, that is
unable to block IFN signalling (Chatziandreou et al.,
2002a). At 18 h p.i., the cells were fixed and stained for
viral NP and for the overexpressed ISGs. Overexpression of
IFIT3, IFI35, ISG15, ISG20 and viperin did not have any
obvious effect on the levels of NP or P (data not shown). In
contrast, and as shown in Fig. 1, cells that transiently
expressed ISG56/IFIT1 were negative for NP.
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We next knocked down the expression of the endogenous
human ISG56/IFIT1 gene in Hep2 and A549 cells using
small hairpin RNA (shRNA; Fig. S1, available in JGV
Online). The cells used here had been engineered
previously to express the bovine viral diarrhea virus
(BVDV) Npro protein constitutively, which renders them
unable to produce IFN, although they are still able to
respond to exogenously added IFN (Carlos et al., 2007;
Hilton et al., 2006). When control cells (i.e. those
that express BVDV-Npro but not shISG56/IFIT1) were
infected with the CPI2 strain of PIV5, a normal pattern
of virus protein synthesis was observed (Fig. 2, lanes 1).
However, virus protein synthesis was dramatically
reduced in cells pre-treated with IFN (Fig. 2, lanes 2).
In striking contrast, a near-normal pattern of virus
protein synthesis was observed in IFN-treated cells with
impaired ISG56/IFIT1 expression (Fig. 2, compare lanes
3 and 4).
We also examined the effects of treating cells with IFN
subsequent to infection. Again, treatment of control cells
with IFN at 8 h p.i. reduced the overall levels of virus
protein synthesis, in particular expression of the M and
HN proteins (compare lanes 5 and 6 in Fig. 2; the position
of the M protein is highlighted by an asterisk in the total
cell extracts). When the ISG56/IFIT1-knockdown cells
were infected with CPI2 and subsequently treated with
IFN, a near-normal pattern of virus protein synthesis was
again observed (compare lanes 7 and 8 in Fig. 2).
Knockdown of ISG56/IFIT1 in naı¨ve Hep2 cells (i.e.
without the expression of BVDV-Npro), which can
produce and respond to IFN and thus begin to inhibit
PIV5 prior to the addition of exogenous IFN to the culture
medium, also restored a near-normal pattern of virus
protein synthesis, even when exogenous IFN was added to
the culture medium (Fig. S2). Similar results were also
obtained with naı¨ve A549 cells (Fig. S3). These results
clearly demonstrated that ISG56/IFIT1 is primarily
responsible for the IFN-induced inhibition of virus protein
synthesis. It was also striking that the effect of IFN on the
levels of virus protein synthesis in Hep2/BVDV-Npro cells
was not due to a general shutdown of protein synthesis, as
the levels of host protein synthesis were similar in IFN pre-
treated, post-treated and untreated cells (Fig. 2; see also
Fig. 5).
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Fig. 1. Transient expression of ISG56/IFIT1 inhibits PIV5. Hep2
cells were transiently transfected with a plasmid containing
haemagglutinin (HA)-tagged ISG56/IFIT1. At 24 h post-transfec-
tion, cells were either mock infected or infected with PIV5 at a high
m.o.i. (10 p.f.u. per cell). At 24 h p.i., the cells were fixed and
immunostained for the viral NP protein (red) and the HA-tagged
ISG56/IFIT1 (green).
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Fig. 2. ISG56/IFIT1 is primarily responsible for the IFN-induced
changes in CPI” protein synthesis. Hep2/BVDV-Npro (control)
cells or Hep2/BVDV-Npro.shISG56/IFIT1 (shISG56) cells were
treated or not with IFN at 8 h prior to infection with a high m.o.i.
of CPI” (IFN pre-treated), or were treated with IFN at 8 h p.i.
(IFN post-treatment). At 20 h p.i., the cells were radioactively
labelled with L-[35S]methionine for 1 h and the viral proteins were
immunoprecipitated. Total cell extracts (left-hand panels) and
immunoprecipitates (right-hand panels) were separated by
electrophoresis through a 4”12 % polyacrylamide gel and the
labelled proteins visualized using a phosphoimager. The position
of the M protein in the total cell extracts is indicated by asterisks.
Samples of the total cell extracts corresponding to the samples in
lanes 5–8 were also immunoblotted for the presence of STAT1
and ISG56/IFIT1 (bottom panel), which are inducible by IFN, and
for b-actin.
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IFN, through the activity of ISG56/IFIT1, induces
alterations in the pattern of virus transcription
We next examined whether the ISG56/IFIT1-induced
inhibition of virus protein synthesis was due to inhibition
of virus transcription or translation. We first undertook a
time-course study of virus mRNA accumulation in the
absence of an IFN response in control cells. For this
analysis, quantitative PCR (qPCR) was used to measure the
relative amounts of NP, P/V, M, HN and L viral mRNAs in
CPI2-infected control cells. The results from this analysis
(Fig. 3) showed that the highest mRNA levels occurred at
around 18 h p.i. and that the general pattern was the same
at all time points examined. A clear gradation of mRNA
levels for the NP, P, HN and L genes was observed, with L
mRNA being the least abundant. As expected, the gradient
was related to the order of these genes within the virus
genome, consistent with a predictable dissociation of the
virus RNA polymerase from the template. The exception to
this was M mRNA, which was always significantly less
abundant than HN mRNA, despite the more proximal
position of the M gene to the 39 promoter (discussed
below). When control cells were treated with IFN at 8 h
prior to infection with CPI2 and the levels of viral mRNA
measured at 20 h p.i., a significant decrease was observed
in the amount of all viral mRNAs (Fig. 4). However,
surprisingly, treating cells with IFN at 8 h after infection
increased, rather than decreased, the amount of all the viral
mRNAs, with the greatest increase noted in the amount of
L mRNA, suggesting that there was less chance of the
polymerase disengaging from the template in cells treated
with IFN after infection. Under these conditions, the level
of M mRNA was higher than that of HN mRNA (Fig. 4). In
contrast to the control cells, treating CPI2-infected Hep2/
BVDV-Npro/shISG56/IFIT1 cells with IFN either prior to or
after infection did not significantly alter either the pattern
or levels of virus transcript accumulation.
The increase in viral mRNA levels observed in control cells
treated with IFN after infection was not reflected in the
levels of virus protein synthesized, which were significantly
reduced in response to IFN (Fig. 2). As, under these
conditions, there was no such marked reduction in the
synthesis of cellular proteins, these data suggested that IFN,
through the action of ISG56/IFIT1, induced a specific
block in the translation of viral mRNAs. To investigate
this further, mRNA was isolated from CPI2-infected
control cells at 20 h p.i. and translated in cell-free rabbit
reticulocyte lysate. In order to compare the pattern of
virus protein synthesis with that in cells, parallel cultures
were also labelled with [35S]methionine. In complete
contrast to the decrease in virus protein synthesis
observed in infected cells, there was an obvious increase
in the amount of all the viral proteins made by in vitro
translation of mRNA isolated from cells that had been
treated with IFN (Fig. 5; note the M protein in total cell
samples has been highlighted with asterisks). This was
consistent with our qPCR data (Fig. 4), which showed
that IFN treatment of cells after infection led to an increase
in viral mRNA synthesis, and demonstrated that the
mRNA remained translatable. In contrast, there was no
increase in the in vitro translation of cellular proteins,
confirming the selective block on viral mRNA transla-
tion in CPI2-infected control cells following IFN treat-
ment. Taken together, these results strongly suggested that
ISG56/IFIT1 selectively inhibits the translation of viral
mRNA.
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Fig. 3. Time course of expression of CPI” mRNA. Hep2/BVDV-
Npro cells were infected at a high m.o.i. (10 p.f.u. per cell) of CPI”
and at various times p.i., the total cell RNA was extracted and
subjected to qPCR for NP, P/V, M, HN and L mRNA. mRNA values
are expressed as the quantity of the gene of interest relative to the
quantity of b-actin mRNA. Results are shown as means±SEM of
duplicate samples in two separate experiments.
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Fig. 4. Analysis of the relative levels of CPI” mRNAs in Hep2/
BVDV-Npro and Hep2/BVDV-Npro/shISG56/IFIT1-infected cells
that were pre-treated (IFN pre) or not (”IFN) with IFN at 8 h prior
to infection with CPI”, or were treated with IFN at 8 h p.i. (IFN
post). At 20 h p.i., total cell RNA was extracted and the levels of
NP, P/V, M, HN and L mRNA relative to b-actin mRNA were
determined by qPCR. Results are shown as means±SEM of
duplicate samples in two separate experiments.
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PIV5 mRNA and 2§-O-methylated caps
It has been suggested recently that the IFIT family proteins
ISG56/IFIT1 and ISG54/IFIT2 can recognize and inhibit
the translation of (viral) mRNA caps that are not 29-O-
methylated and that this can act as a mechanism by which
the host cell can distinguish self from non-self mRNA
during virus infection (Daffis et al., 2010). Although the
PIV5 polymerase is predicted to have 29-O-methyltransfer-
ase activity (Ferron et al., 2002), we tested whether the
CPI2mRNA cap was methylated at 29-O positions. mRNA
was isolated from mock- or CPI2-infected control cells at
20 h p.i. and the incorporation of 3H-labelled methyl
groups from donor S-adenosyl-methionine was monitored
by in vitro methylation assays using the vaccinia virus 29-O-
methyltransferase VP39 (Schnierle et al., 1992). No
detectable incorporation of 3H was observed in mRNA
isolated from mock-infected or CPI2-infected cells (Fig.
6), suggesting that the viral mRNA was indeed 29-O-
methylated.
ISG56/IFIT1 activity indirectly influences the
formation of viral cytoplasmic bodies
In addition to inducing alterations in the pattern of virus
protein synthesis, IFN also alters the distribution of virus
proteins in CPI2-infected cells such that the NP proteins
become primarily localized in cytoplasmic bodies (Carlos
et al., 2009). We therefore also examined the distribution
of the NP and P proteins in naı¨ve and ISG56/IFIT1-
knockdown cells. For these experiments, we used A549 cells
rather than Hep2 cells because they give better-quality
immunofluorescence data. As can be observed in Fig. 7, in
untreated control A549 cells (i.e. those that constitutively
express BVDV-Npro), NP was distributed primarily
throughout the cytoplasm, whilst in cells that had been
treated with exogenous IFN, NP was located primarily in
cytoplasmic bodies. In marked contrast, following treat-
ment of ISG56/IFIT1-knockdown cells with IFN, the
distribution of NP was distributed primarily throughout
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the cytoplasm, resembling the pattern observed in control
cells that had not been treated with IFN.
Although ISG56/IFIT1 is the major ISG that
inhibits PIV5, other ISGs also contribute to the
antiviral activity of IFN
To investigate the influence of ISG56/IFIT1 on the
production of infectious virus, the amount of infectious
virus in the culture medium of CPI2-infected control and
ISG56/IFIT1-knockdown cells was determined 2 days after
infection (Fig. 8). Pre-treatment of control cells with IFN
reduced the titres by ~5 logs (from ~108 to ~103 p.f.u.
ml21). In contrast, IFN pre-treatment of the ISG56/IFIT1
knockdown cells only reduced titres by approximately
tenfold. These results clearly showed that, whilst ISG56/
IFIT1 is a major contributor to IFN-induced inhibition of
CPI2 growth, other ISGs must also contribute to the
induction of an IFN-induced antiviral state. This conclu-
sion was supported by the observation that, whilst
knockdown of ISG56/IFIT1 facilitated CPI2 plaque
formation on naı¨ve A549 cells (which do not normally
support CPI2 plaques), the plaques that were formed were
not as large as those observed on control cells (i.e. those
that expressed BVDV-Npro; Fig. 8b).
DISCUSSION
Although PIV5 encodes a powerful IFN antagonist, the V
protein, that limits IFN induction and blocks IFN
signalling, its ability to circumvent the IFN response is
not absolute. Thus, during plaque development, a few
virus-infected cells produce IFN, which induces an antiviral
state in the uninfected cells surrounding the plaque,
thereby slowing the spread of virus (Carlos et al., 2009;
Chen et al., 2010). Here, we set out to understand in more
detail how IFN induces an antiviral state to PIV5 by
identifying the ISGs that inhibit virus replication. The
results presented here demonstrated that, although other
ISGs contribute to a minor degree to the IFN-induced
antiviral state, remarkably ISG56/IFIT1 is primarily
responsible for the observed IFN-induced alterations in
PIV5 transcription and protein synthesis.
ISG56/IFIT1 is a member of a family of proteins whose
expression is strongly induced from very low basal levels by
IFN, and by activated IRF-3 (reviewed by Fensterl & Sen,
2011). IFIT1 family members have structural features in
common: all contain several tetratricopeptide repeats
representing helix–turn–helix motifs that mediate a variety
of protein–protein interactions. The best-studied cellular
function of ISG56/IFIT1 is the inhibition of translation
initiation (Guo et al., 2000; Terenzi et al., 2005) that is
mediated through its binding to eukaryotic initiation factor
3 (eIF3). In addition to a general inhibition of mRNA
translation, it has been suggested recently that ISG56/IFIT1
specifically inhibits the translation of viral mRNAs that are
not appropriately capped. Eukaryotic host mRNAs are
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shISG56) and naı¨ve A549/BVDV-Npro cells (nA549). Monolayers
of cells in six-well plates were infected with CPI”. At 7 days p.i.,
the cells were fixed and the virus plaques visualized by
immunostaining the monolayers with a pool of mAbs to the NP
and P proteins.
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modified at the 59 end by the addition of a 59–59-linked,
non-templated guanosine residue, which is methylated at
N7, and additionally have 29-O-methylation of the ribose
ring of the first one or two templated bases. Whilst N7-
methylation of the guanosine increases translational
efficiency, the reason for 29-O-methylation of the ribose
sugars is unclear (Furuichi & Shatkin, 2000). However,
recent work has suggested that lack of methylation of the
29 ribose might allow cells to distinguish self from non-
self RNA (Daffis et al., 2010; Pichlmair et al., 2011; Zu¨st
et al., 2011). To avoid this recognition, it is suggested
that viruses that replicate in the cytoplasm have evolved
both N7- and 29-O-methyltransferases to methylate their
viral mRNA cap structures. West Nile virus, mouse
coronavirus and vaccinia virus mutants lacking 29-O-
methyltransferase activity have enhanced sensitivity to IFN
and the antiviral activity of IFIT1 proteins (Zu¨st et al.,
2011). It has also been reported recently that ISG56/IFIT1
binds uncapped triphosphorylated RNA, which is found at
the 59 ends of the genomic and antigenomic RNA of some
RNA viruses, as well as at the ends of some viral transcripts
(Pichlmair et al., 2011). However, the relationship between
this property and the ability to preferentially inhibit
translation of mRNA with cap structures lacking 29-O-
methyl groups but still having an N7-methylguanosine
(and which therefore cannot be triphosphorylated) is
unclear.
The results presented here showed that ISG56/IFIT1
selectively inhibited PIV5 mRNA translation. Our inability
to detect any un-29-O-methylated mRNA within the
sensitivity of the test suggested that the selective inhibition
is unlikely to be due to any deficiency in cap 29-O-
methylation, although we cannot rule out the possibility
that cells may contain small amounts of CPI2mRNAs that
are not 29-O-methylated, which may activate ISG56/IFIT1.
In this regard, it is of note that, whilst the PIV5 viral
polymerase has the absolutely conserved residues for 29-O-
methyltransferase enzymes (Ferron et al., 2002), PIV5
(like Newcastle disease virus, parainfluenza virus type 2,
mumps virus and simian virus 41) has an alanine instead
of the first glycine (position G1804 in Sendai virus L) in
a glycine-rich motif in the methyltransferase domain of
other members of the order Mononegavirales that may
influence the efficiency of 29-O-methylation (Murphy et al.,
2010).
As well as selectively inhibiting translation of PIV5
mRNAs, it is also clear that ISG56/IFIT1 affects virus
transcription. In support of the data presented here, using
Northern blot analysis to examine the effects of IFN on the
transcription of CPI2 mRNAs in Vero cells (which cannot
produce but can respond to IFN), we reported that there
was an increase in NP and P mRNA transcription following
IFN treatment p.i. (Carlos et al., 2005). How ISG56/IFIT1
activity affects virus transcription remains to be estab-
lished. It may be that the ISG56/IFIT1-mediated inhibition
of viral protein synthesis leads indirectly to an alteration in
the pattern of virus transcription. For example, a change in
the ratio of a particular virus protein to other viral proteins
[e.g. the V protein, which has a relatively short half life
(Fearns et al., 1994) and negatively regulates viral RNA
synthesis (Lin et al., 2005)] results in an increase in virus
transcription and/or alterations to the processivity of the
viral polymerase–transcription complex. Alternatively, it
may be that ISG56/IFIT1 directly interacts with the viral
polymerase, altering its activity. In this regard, it is of note
that ISG56/IFIT1 binds to and inactivates the viral E1
helicase of human papillomavirus, which is essential for
viral DNA replication (Terenzi et al., 2008).
In our previous studies, which used Northern blot analysis
to examine the pattern of CPI2 transcription in Vero cells
treated with IFN p.i., as well as noting an increase in the
levels of NP and P mRNA, we also noted a significant
decrease in the levels of full-length HN mRNAs (Carlos
et al., 2005). At the time, we speculated that this was either
because the polymerase was more likely to disengage from
the template as it proceeded down the genome in cells
treated with IFN, or that IFN somehow affected the
stability of the HN mRNA. Given that we have shown that,
in IFN-treated PIV5-infected control Hep2 cells, there is an
increase in the levels of all the viral mRNAs, this suggests
that the latter explanation may have been correct.
Alternatively, there may be a difference in the effects of
IFN on Vero and Hep2 cells.
We also suggested previously that IFN may modulate and
influence the establishment and maintenance of persistent
infections with PIV5 by favouring the formation of virus
cytoplasmic bodies (which have been shown to contain
genomic RNA), and that these may be sites at which the
virus can establish a quiescent infection, hiding both from
innate intracellular antiviral responses and adaptive
immune responses (Carlos et al., 2009; Chatziandreou
et al., 2002b; Fearns et al., 1994). In this respect, it is of
interest that the most marked reduction in the viral
proteins synthesized in cells either pre- or post-treated with
IFN encoded proteins downstream of the P gene, in
particular the M protein, whilst the synthesis of NP and P,
although inhibited, remain relatively high. The reason for
these apparent differences in the effects of IFN on the
relative inhibition of the different viral proteins remains
unclear but may simply reflect the stability of the proteins,
with NP and P being very stable and M and HN relatively
unstable. Nevertheless, a consequence of this change in the
relative levels of the viral proteins (i.e. the increase in the
relative amounts of NP and P compared with the other
virus proteins) might favour the formation of cytoplasmic
bodies. Indeed, the fact that knockdown of ISG56/IFIT1
prevented the formation of inclusion bodies, and that
inducible co-expression of NP and P in cell lines leads to
the formation of large cytoplasmic aggregates (in the
absence of an IFN response; Precious et al., 1995), suggests
that it is the balance of viral proteins that are synthesized
that influences the formation of viral cytoplasmic bodies
rather than the induction of a specific cellular ISG that
drives their formation.
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METHODS
Cells, viruses and IFN. Vero, Huh7, A549 and Hep2 cells and their
respective derivatives were grown as monolayers in 25 or 75 cm2
tissue-culture flasks in Dulbecco’s modified Eagle’s medium supple-
mented with 10 % fetal calf serum at 37 uC. When needed, cells
were treated with human recombinant IFN (Roferon-A; Roche)
at 1000 U ml21. The CPI2 isolate was grown and titrated in Vero
cells.
Preparation of radiolabelled antigen extracts, immunoprecipi-
tation and SDS-PAGE. The methodology used has been described
elsewhere (Carlos et al., 2005). Briefly, cells were mock infected or
infected with CPI2 and at 8 h p.i. were treated with IFN or left
untreated for 12 h and then metabolically labelled for 1 h with L-
[35S]methionine (500 Ci mmol21; MP Biomedical). After labelling,
the cells were lysed in immunoprecipitation buffer, sonicated and
centrifuged for 30 min at 12 000 g to remove solid material.
Immunocomplexes were formed by incubating soluble antigens with
protein G–Sepharose (Sigma), pre-coupled with a mix of mAbs to the
viral proteins NP, P, HN and M. The proteins in immunocomplexes
were dissociated by heating for 5 min at 100 uC and analysed by SDS-
PAGE. The gels were fixed, stained and dried, and the resolved bands
visualized by phosphorimage analysis.
Plasmids and generation of cells expressing shRNA to ISG56/
IFIT1. The mammalian expression vector containing the full-length
haemagglutinin (HA)-tagged IFIT1/ISG56 gene was a kind gift from
Dr F. Weber (Institute for Virology, Philipps University Marburg,
Germany). Lentivirus vector used for the expression of ISG56/IFIT1
shRNA sequence was based on pLKO.1puro, as described by Everett
et al. (2007). A derivative of the vector expressing the blasticidin
resistance gene (pLKO.BLAST) was obtained from Dr R. D. Everett
(CVR, University of Glasgow, UK). Double-stranded oligonucleotides
corresponding to the target sequences were cloned into pLKO.BLAST.
The target sequences for human ISG56 were for region 1 (59-
GGATAAAGCTCTTGAGTTA-39) and region 2 (59-CTACAAAT-
TGGAAGGAAAT-39) (Li et al., 2009). The method used to isolate
lentivirus stock has been described previously (Hilton et al., 2006).
Lentivirus-infected cells were selected with blasticidin (10 mg ml21)
and maintained for 4 weeks in medium containing blasticidin.
Immunofluorescence. For immunofluorescence analysis, cells were
grown on 10 mm diameter coverslips (General Scientific Co.) in
individual wells of six-well plates. Cells were transiently transfected
with a plasmid encoding HA-tagged ISG56/IFIT1. At 24 h post-
transfection, cells were infected with the different viruses. At 24 h p.i.,
monolayers of cells on coverslips were incubated in fixing solution
(5 % formaldehyde in PBS) for 15 min at room temperature,
permeabilized (0.5 % NP-40, 10 % sucrose in PBS) for 10 min and
washed three times in PBS containing 1 % FCS. To detect the
proteins of interest, cell monolayers were incubated with 20 ml of
appropriately diluted primary antibody for 1 h. For CPI2 infection,
mAbs to NP and P proteins were used, named SV5-NP-a and SV5-P-
e, respectively (Randall et al., 1987). To detect overexpressed ISG56/
IFIT1, anti-HA rabbit polyclonal antibody (Sigma) was used. After
subsequent incubation with primary antibody, the cells were washed
several times with 1 % FCS in PBS and incubated for 1 h with
secondary Texas Red-conjugated goat anti-mouse IgG (for viral
proteins) or FITC-conjugated goat anti-rabbit IgG for ISG56/IFIT1
detection (Sera Lab).
qPCR. Total cellular RNA was extracted from infected cells using
TRIzol (Invitrogen). Two micrograms of RNA was subsequently used
for RT-PCR. Fragments of ~200 bp were amplified with primers for
NP, P, M, HN and L. b-Actin was used as a reference gene. Primer
sequences were: NP: 59-AGGGTAGAGATCGATGGCT-39 (forward)
and 59-GTCTGACCACCATTCCCTT-39 (reverse); P: 59-AATACCA-
CCAGGGGTCACAG-39 (forward) and 59-CGAGCACCCAAACTG-
TGCTT-39 (reverse); M: 59-TCATGAGCCACTGGTGACAT-39 (for-
ward) and 59-TGGAATTCCCTCAGTTGTCC-39 (reverse); HN: 59-
AACTCTGCAGTCGCTCTACC-39 (forward) and 59-GCAATCTG-
ACACTTGGCCCA-39 (reverse); L: 59-TCCAAGTGATGACTTTG-
AATT-39 (forward) and 59-CCATACTCATTACTCGTGTGCC-39
(reverse); and b-actin: 59-ACCAACTGGGACGACATGGAG-39 (for-
ward) and 59-TAGCACAGCCTGGATAGCAAC-39 (reverse). The
plotted values of mRNA were expressed as the quantity of the gene
of interest relative to the quantity of the reference gene, to obtain
normalized and relative expression values. Each sample was
performed in duplicate on the same qPCR plate in two separate
experiments. A non-template sample and a non-reverse transcriptase
sample were analysed routinely as negative controls. Data were
collected using a 7300 Real-time PCR System (Applied Biosystems).
In vitro methylation assay. Poly(A)-containing RNA was isolated
from 1.56107 mock- or CPI2-infected A549 cells with an Oligotex
Direct mRNA Mini kit according to the manufacturer’s instructions
(Qiagen). In vitro-transcribed N7-methyl-capped model RNA (m7-
Cap-RNA) encoding the NP of mouse hepatitis coronavirus was
generated using a T7 RiboMax Express Large Scale RNA Production
System (Promega). The N7-methylated cap was added using the
ScriptCap m7G Capping System according to the manufacturer’s
recommendation (Cellscript). 29-O-Methylation reactions were
carried out as described previously (Zu¨st et al., 2011). Briefly,
100 ng of in vitro-transcribed m7-Cap-RNA or 300–1500 ng
poly(A)-containing RNA derived from virus-infected cells or the
corresponding amount of poly(A)-containing RNA from uninfected
cells was incubated for 1 h at 37 uC with ScriptCap 29-O-
methyltransferase (Cellscript) in the presence of 0.5 mM S-adeno-
sylmethionine and 1.4 mM 3H-labelled S-adenosylmethionine (78 Ci
mmol21; Perkin Elmer). Reactions were purified with SigmaSpin
Post-Reaction Clean-Up columns (Sigma-Aldrich) and eluates were
mixed with 2 ml Ultima Gold scintillation fluid for measurement of
3H incorporation with a Packard Tri-Carb liquid scintillation
counter (Perkin Elmer).
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